Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate‐to‐severe chronic kidney disease (AWARD‐7)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate‐to‐severe chronic kidney disease (AWARD‐7)

Published:2019-03-29 Issue:6 Volume:21 Page:1493-1497
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Tuttle Katherine R.¹,Lakshmanan Mark C.²,Rayner Brian³,Zimmermann Alan G.²,Woodward Brad²,Botros Fady T.²^ORCID

Affiliation:

1. Providence Health CareUniversity of Washington Spokane Washington

2. Eli Lilly and Company Lilly Diabetes Development, Indianapolis Indiana

3. Division of Nephrology and HypertensionGroote Schuur Hospital and University of Cape Town Cape Town South Africa

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13668

Reference18 articles.

1. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease;KDOQI;Am J Kidney Dis,2007

2. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

3. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies;Davies M;Clin Pharmacol,2016

4. Diabetic Kidney Disease: A Report From an ADA Consensus Conference

5. Effect of large weight reductions on measured and estimated kidney function

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes;New England Journal of Medicine;2024-07-11

2. Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease;Journal of Clinical Medicine;2023-12-29

3. Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis;Diabetes Care;2023-06-02

4. Indicators of Kidney Fibrosis in Patients with Type 2 Diabetes and Chronic Kidney Disease Treated with Dulaglutide;American Journal of Nephrology;2023

5. Effect of once-weekly dulaglutide on renal function in patients with chronic kidney disease;PLOS ONE;2022-08-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3